Skip to main content
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
// //

Vbi Vaccines Inc CS NASDAQ: VBIV-Q

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time

Today's Trading

Day Low 3.15
Day High 3.33
Open:3.23
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA.

Fundamentals

Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Strong Buy

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

The Surge in New Cases Reinforces the Importance of a Healthy Lifestyle
- PR Newswire - PRF - Mon Aug 9, 8:00AM CDT
PR Newswire - PRF - CMTX
Mon Aug 9, 8:00AM CDT
/PRNewswire/ -- While most of the economy has reopened, the number of new cases is once again on the rise. This time, two variants of COVID-19, the delta and lambda variants, are causing the numbers of newly inflected to rise. Delta is the most recent of four coronavirus mutations added to the World Health Organization's and Centers for Disease Control and Prevention's "variants of concern" lists. "[Delta is] mutating compared to other viruses incredibly quickly. I think a big part of that is because there is a significant percentage of people who are getting infected and are asymptomatic," Dr. , a , told KGO-TV according to . "The world is really a huge petri dish." Todos Medical Ltd. (OTC: TOMDF), Agenus Inc. (NASDAQ: AGEN), Hologic, Inc. (NASDAQ: HOLX), VBI Vaccines Inc. (NASDAQ: VBIV), iBio, Inc. (NYS: IBIO)
VBI Vaccines Announces Second Quarter 2021 Financial Results and Provides Corporate Update
- Business Wire - Mon Aug 2, 7:00AM CDT
Business Wire - CMTX
Mon Aug 2, 7:00AM CDT
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today reported financial results for the second quarter ending June 30, 2021 and provided a corporate update.
VBI Vaccines Appoints Linda Bain to Board of Directors
- Business Wire - Wed Jul 7, 7:00AM CDT
Business Wire - CMTX
Wed Jul 7, 7:00AM CDT
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Linda Bain, Chief Financial Officer of Codiak BioSciences, Inc., has joined its Board of Directors. Ms. Bain is an accomplished financial and business executive with more than two decades of finance, strategy, and board experience in both small and large public companies in the biotechnology and pharmaceutical industry.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 2.80 +18.21% increase
on 08/18/21
Period Open:2.88
Price movement based on the high, low and last over the given period.
3.81 -13.12% decrease
on 09/01/21
+0.43 (+14.93%) increase
since 08/17/21
3-Month 2.73 +21.25% increase
on 08/17/21
Period Open:3.95
Price movement based on the high, low and last over the given period.
4.31 -23.20% decrease
on 06/29/21
-0.64 (-16.20%) decrease
since 06/17/21
52-Week 2.07 +59.90% increase
on 11/10/20
Period Open:3.76
Price movement based on the high, low and last over the given period.
4.83 -31.47% decrease
on 02/10/21
-0.45 (-11.97%) decrease
since 09/17/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies